低剂量阿糖胞苷治疗成人初诊朗格汉斯细胞组织细胞增生症的2期研究
这项单中心2期前瞻性研究(NCT04121819)纳入61例初诊成人朗格汉斯细胞组织细胞增生症患者,给予皮下阿糖胞苷100 mg/m2连续5天、35天为一周期共12周期治疗。总缓解率93.4%,中位随访30个月后21例(34.4%)复发、无死亡,估计3年总生存率100.0%、无事件生存率58.5%。多因素分析显示≥3个器官受累和基线肺受累为无事件生存的不良预后因素。
要点
- 皮下阿糖胞苷100 mg/m2连用5天、35天为一周期共12周期,总缓解率93.4%,完全缓解32.7%。
- 中位随访30个月,21例(34.4%)复发、无死亡,估计3年总生存率100.0%、无事件生存率58.5%。
- ≥3个器官受累(P=0.007;HR 3.937,95%CI 1.456-9.804)和基线肺受累(P=0.028;HR 2.976,95%CI 1.126-7.874)为无事件生存不良预后因素。
核心结论
- 阿糖胞苷单药是初诊成人朗格汉斯细胞组织细胞增生症有效且安全的方案,而基线肺受累或≥3个器官受累提示预后不良。
研究设计与样本
- 单中心2期前瞻性研究(NCT04121819),2019年10月至2022年6月纳入61例初诊成人朗格汉斯细胞组织细胞增生症患者,均为多系统或多灶性单系统疾病。
- 皮下阿糖胞苷100 mg/m2连用5天,35天为一周期,共12周期;主要终点为无事件生存。
主要发现
- 中位年龄33岁(范围18-66);12例(19.7%)有肝脏受累,其中2例同时有脾受累。
- 43例接受二代测序,BRAF改变最常见(44.2%),其次为TP53(16.3%)、MAP2K1(14.0%)和IDH2(11.6%);MAPK通路改变见于28例(65.1%)。
- 总缓解率93.4%,其中完全缓解20例(32.7%)、部分缓解37例(60.7%)。
- 中位随访30个月后21例(34.4%)复发、无死亡;估计3年总生存率100.0%、无事件生存率58.5%。
- 多因素分析显示≥3个器官受累(P=0.007;HR 3.937,95%CI 1.456-9.804)和基线肺受累(P=0.028;HR 2.976,95%CI 1.126-7.874)为无事件生存的不良预后因素。
关键数值与推荐
- 最常见3-4级毒性为中性粒细胞减少(27.9%)、血小板减少(1.6%)和恶心(1.6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Langerhans cell histiocytosis (LCH) lacks a standardized first-line therapy. This single-center, phase 2 prospective study (NCT04121819) enrolled 61 newly diagnosed adult LCH patients with multisystem or multifocal single system disease from October 2019 to June 2022. Subcutaneous cytarabine (100 mg/m2 for 5 days) was administered in 35-day cycles for 12 total cycles. The primary endpoint was event-free survival (EFS). The median age was 33 years (range 18-66). Twelve patients (19.7%) had liver involvement, of which 2 also had spleen involvement. Among 43 patients undergoing next-generation sequencing, BRAF alterations (44.2%) were most frequent, followed by TP53 (16.3%), MAP2K1 (14.0%) and IDH2 (11.6%). MAPK pathway alterations occurred in 28 patients (65.1%). The overall response rate was 93.4%, with 20 (32.7%) achieving complete response and 37 (60.7%) partial response. After a median 30 months follow-up, 21 (34.4%) relapsed without deaths. Estimated 3-year OS and EFS were 100.0% and 58.5%, respectively. Multivariate analysis identified ≥3 involved organs (P = 0.007; HR 3.937, 95% CI: 1.456-9.804) and baseline lung involvement (P = 0.028; HR 2.976, 95% CI: 1.126-7.874) as poor prognostic factors for EFS. The most common grade 3-4 toxicities were neutropenia (27.9%), thrombocytopenia (1.6%), and nausea (1.6%). In conclusion, cytarabine monotherapy is an effective and safe regimen for newly diagnosed adults, while baseline lung or ≥3 involved organs confers poor prognosis.
引用
- Chang L, Lang M, Lin H, et al. Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia. 2024. PMID: 38388646. doi:10.1038/s41375-024-02174-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。